In myelofibrosis, a myeloproliferative and fibrotic disease of the bone marrow, serum PRO-C3 and PRO-C4 have already been described as potential biomarkers that correlate with increased type III and IV collagen in the bone marrow [36,37,38,39,40]. This evidence concerns the gene C3 and glycogen storage disease VI.